{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,24]],"date-time":"2026-10-24T00:18:29Z","timestamp":1792801109447,"version":"4.5.0"},"reference-count":56,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T00:00:00Z","timestamp":1778716800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T00:00:00Z","timestamp":1783641600000},"content-version":"vor","delay-in-days":57,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"funder":[{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82460821"],"award-info":[{"award-number":["82460821"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"crossref","award":["82270925, 82470892"],"award-info":[{"award-number":["82270925, 82470892"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Innovative Drug Research and Development National Science and Technology Major Project","award":["2025ZD1802602"],"award-info":[{"award-number":["2025ZD1802602"]}]},{"DOI":"10.13039\/501100021171","name":"Guangdong Basic and Applied Basic Research Foundation","doi-asserted-by":"crossref","award":["2025A1515010594"],"award-info":[{"award-number":["2025A1515010594"]}],"id":[{"id":"10.13039\/501100021171","id-type":"DOI","asserted-by":"crossref"}]},{"name":"High-level Innovative Research Institute of the Department of Science and Technology of Guangdong Province","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}],"id":[{"id":"https:\/\/ror.org\/00tjzgn92","id-type":"ROR","asserted-by":"crossref"}]},{"name":"High-level Innovative Research Institute of the Department of Science and Technology of Guangdong Province","award":["2021B0909050003"],"award-info":[{"award-number":["2021B0909050003"]}],"id":[{"id":"https:\/\/ror.org\/00tjzgn92","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100011198","name":"State Key Laboratory of Drug Research","doi-asserted-by":"crossref","award":["SKLDR-2025-KF-07"],"award-info":[{"award-number":["SKLDR-2025-KF-07"]}],"id":[{"id":"10.13039\/501100011198","id-type":"DOI","asserted-by":"crossref"}]},{"name":"Lin Gang Laboratory","award":["LGL-2612-22"],"award-info":[{"award-number":["LGL-2612-22"]}]},{"name":"High-level New R&D Institute of the Department of Science and Technology of Guangdong Province","award":["2019B090904008"],"award-info":[{"award-number":["2019B090904008"]}],"id":[{"id":"https:\/\/ror.org\/00tjzgn92","id-type":"ROR","asserted-by":"crossref"}]},{"DOI":"10.13039\/501100017291","name":"Zhongshan Science and Technology Bureau","doi-asserted-by":"publisher","award":["CXTD2023009"],"award-info":[{"award-number":["CXTD2023009"]}],"id":[{"id":"10.13039\/501100017291","id-type":"DOI","asserted-by":"publisher"}]},{"name":"Traditional Chinese medicine inheritance innovation development research project of Zhongshan City","award":["2024B3002"],"award-info":[{"award-number":["2024B3002"]}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Nanobiotechnol"],"DOI":"10.1186\/s12951-026-04511-1","type":"journal-article","created":{"date-parts":[[2026,5,14]],"date-time":"2026-05-14T11:03:14Z","timestamp":1778756594000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Galactosylated LNP-mediated hepatic Sam68 silencing improves glucose homeostasis in diabetes by suppressing gluconeogenesis"],"prefix":"10.1186","volume":"24","author":[{"given":"Ning","family":"Wang","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Xiang","family":"Cao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jing","family":"Lai","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yifan","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ao","family":"Yu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Siyu","family":"An","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yucheng","family":"Gao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ebenezeri Erasto","family":"Ngowi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Juan","family":"Yang","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Chang","family":"Fu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Junyu","family":"Xu","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Li","family":"Tian","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Haozhe","family":"Piao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shiyang","family":"Shen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aijun","family":"Qiao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,5,14]]},"reference":[{"issue":"1","key":"4511_CR1","doi-asserted-by":"publisher","first-page":"61","DOI":"10.7748\/ns.2021.e11709","volume":"37","author":"L Cloete","year":"2022","unstructured":"Cloete L. Diabetes mellitus: an overview of the types, symptoms, complications and management. Nurs Stand. 2022;37(1):61\u20136.","journal-title":"Nurs Stand"},{"issue":"1","key":"4511_CR2","first-page":"30","volume":"93","author":"MP Russo","year":"2023","unstructured":"Russo MP, et al. Prevalence of diabetes, epidemiological characteristics and vascular complications. Arch Cardiol Mex. 2023;93(1):30\u20136.","journal-title":"Arch Cardiol Mex"},{"issue":"10365","key":"4511_CR3","doi-asserted-by":"publisher","first-page":"1803","DOI":"10.1016\/S0140-6736(22)01655-5","volume":"400","author":"E Ahmad","year":"2022","unstructured":"Ahmad E, et al. Type 2 diabetes. Lancet. 2022;400(10365):1803\u201320.","journal-title":"Lancet"},{"issue":"10397","key":"4511_CR4","doi-asserted-by":"publisher","first-page":"203","DOI":"10.1016\/S0140-6736(23)01301-6","volume":"402","author":"regional Global","year":"2023","unstructured":"Global regional, national burden of diabetes. from 1990 to 2021, with projections of prevalence to 2050: a systematic analysis for the Global Burden of Disease Study 2021. Lancet. 2023;402(10397):203\u201334.","journal-title":"Lancet"},{"issue":"3","key":"4511_CR5","doi-asserted-by":"publisher","first-page":"337","DOI":"10.1016\/j.ecl.2021.05.013","volume":"50","author":"MG Tinajero","year":"2021","unstructured":"Tinajero MG, et al. An Update on the Epidemiology of Type 2 Diabetes: A Global Perspective. Endocrinol Metab Clin North Am. 2021;50(3):337\u201355.","journal-title":"Endocrinol Metab Clin North Am"},{"issue":"18","key":"4511_CR6","doi-asserted-by":"publisher","first-page":"e2100275","DOI":"10.1002\/advs.202100275","volume":"8","author":"S Demir","year":"2021","unstructured":"Demir S, et al. Emerging Targets in Type 2 Diabetes and Diabetic Complications. Adv Sci (Weinh). 2021;8(18):e2100275.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"4511_CR7","doi-asserted-by":"publisher","first-page":"1094","DOI":"10.3390\/ijms26031094","volume":"26","author":"E M\u0142ynarska","year":"2025","unstructured":"M\u0142ynarska E, et al. Type 2 diabetes mellitus: new pathogenetic mechanisms, treatment and the most important complications. Int J Mol Sci. 2025;26(3):1094.","journal-title":"Int J Mol Sci"},{"issue":"10467","key":"4511_CR8","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(24)02317-1","volume":"404","author":"Worldwide trends in diabetes","year":"2024","unstructured":"Worldwide trends in diabetes. prevalence and treatment from 1990 to 2022: a pooled analysis of 1108 population-representative studies with 141 million participants. Lancet. 2024;404(10467):2077\u201393.","journal-title":"Lancet"},{"issue":"1","key":"4511_CR9","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1007\/s00125-025-06581-6","volume":"69","author":"CJ Bailey","year":"2026","unstructured":"Bailey CJ. Pharmacological therapies for type 2 diabetes: future approaches. Diabetologia. 2026;69(1):20\u201335.","journal-title":"Diabetologia"},{"issue":"3","key":"4511_CR10","doi-asserted-by":"publisher","first-page":"495","DOI":"10.1007\/s12079-023-00730-5","volume":"17","author":"HY Zheng","year":"2023","unstructured":"Zheng HY, et al. Biological functions of CRTC2 and its role in metabolism-related diseases. J Cell Commun Signal. 2023;17(3):495\u2013506.","journal-title":"J Cell Commun Signal"},{"issue":"6474","key":"4511_CR11","doi-asserted-by":"publisher","first-page":"871","DOI":"10.1038\/368871a0","volume":"368","author":"S Fumagalli","year":"1994","unstructured":"Fumagalli S, et al. A target for Src in mitosis. Nature. 1994;368(6474):871\u20134.","journal-title":"Nature"},{"issue":"2","key":"4511_CR12","first-page":"73","volume":"1653","author":"KE Lukong","year":"2003","unstructured":"Lukong KE, et al. Sam68, the KH domain-containing superSTAR. Biochim Biophys Acta. 2003;1653(2):73\u201386.","journal-title":"Biochim Biophys Acta"},{"issue":"2","key":"4511_CR13","doi-asserted-by":"publisher","first-page":"167","DOI":"10.1016\/j.molcel.2011.05.007","volume":"43","author":"P Ramakrishnan","year":"2011","unstructured":"Ramakrishnan P, et al. Sam68 is required for both NF-\u03baB activation and apoptosis signaling by the TNF receptor. Mol Cell. 2011;43(2):167\u201379.","journal-title":"Mol Cell"},{"issue":"2","key":"4511_CR14","doi-asserted-by":"publisher","first-page":"187","DOI":"10.1016\/j.molcel.2012.02.007","volume":"46","author":"M Huot","year":"2012","unstructured":"Huot M, et al. The Sam68 STAR RNA-binding protein regulates mTOR alternative splicing during adipogenesis. Mol Cell. 2012;46(2):187\u201399.","journal-title":"Mol Cell"},{"issue":"3","key":"4511_CR15","doi-asserted-by":"publisher","first-page":"181","DOI":"10.1530\/JOE-14-0727","volume":"225","author":"J Zhou","year":"2015","unstructured":"Zhou J, et al. Inhibition of Sam68 triggers adipose tissue browning. J Endocrinol. 2015;225(3):181\u20139.","journal-title":"J Endocrinol"},{"issue":"1","key":"4511_CR16","doi-asserted-by":"publisher","first-page":"3","DOI":"10.3892\/ijmm.2024.5444","volume":"55","author":"C Jim\u00e9nez-Cortegana","year":"2025","unstructured":"Jim\u00e9nez-Cortegana C, et al. Role of Sam68 in different types of cancer (review). Int J Mol Med. 2025;55(1):3.","journal-title":"Int J Mol Med"},{"issue":"1","key":"4511_CR17","doi-asserted-by":"publisher","first-page":"89","DOI":"10.1007\/s00018-023-05108-9","volume":"81","author":"V Gowd","year":"2024","unstructured":"Gowd V, et al. Role of Sam68 as an adaptor protein in inflammatory signaling. Cell Mol Life Sci. 2024;81(1):89.","journal-title":"Cell Mol Life Sci"},{"issue":"8","key":"4511_CR18","doi-asserted-by":"publisher","first-page":"e21772","DOI":"10.1096\/fj.202100021R","volume":"35","author":"A Qiao","year":"2021","unstructured":"Qiao A, et al. Ablation of Sam68 in adult mice increases thermogenesis and energy expenditure. Faseb j. 2021;35(8):e21772.","journal-title":"Faseb j"},{"issue":"19","key":"4511_CR19","doi-asserted-by":"publisher","first-page":"11469","DOI":"10.3390\/ijms231911469","volume":"23","author":"A Qiao","year":"2022","unstructured":"Qiao A, et al. Hepatic Sam68 regulates systemic glucose homeostasis and insulin sensitivity. Int J Mol Sci. 2022;23(19):11469.","journal-title":"Int J Mol Sci"},{"issue":"1","key":"4511_CR20","doi-asserted-by":"publisher","first-page":"3340","DOI":"10.1038\/s41467-021-23624-9","volume":"12","author":"A Qiao","year":"2021","unstructured":"Qiao A, et al. Sam68 promotes hepatic gluconeogenesis via CRTC2. Nat Commun. 2021;12(1):3340.","journal-title":"Nat Commun"},{"issue":"6","key":"4511_CR21","doi-asserted-by":"publisher","first-page":"421","DOI":"10.1038\/s41573-019-0017-4","volume":"18","author":"RL Setten","year":"2019","unstructured":"Setten RL, et al. The current state and future directions of RNAi-based therapeutics. Nat Rev Drug Discov. 2019;18(6):421\u201346.","journal-title":"Nat Rev Drug Discov"},{"issue":"5","key":"4511_CR22","doi-asserted-by":"publisher","first-page":"341","DOI":"10.1038\/s41573-024-00912-9","volume":"23","author":"Q Tang","year":"2024","unstructured":"Tang Q, et al. RNAi-based drug design: considerations and future directions. Nat Rev Drug Discov. 2024;23(5):341\u201364.","journal-title":"Nat Rev Drug Discov"},{"issue":"1","key":"4511_CR23","doi-asserted-by":"publisher","first-page":"13","DOI":"10.1016\/j.molmed.2023.10.005","volume":"30","author":"S Guo","year":"2024","unstructured":"Guo S, et al. Three \u2018E\u2019 challenges for siRNA drug development. Trends Mol Med. 2024;30(1):13\u201324.","journal-title":"Trends Mol Med"},{"issue":"7","key":"4511_CR24","doi-asserted-by":"publisher","first-page":"1283","DOI":"10.1038\/s12276-023-00998-y","volume":"55","author":"I Ahn","year":"2023","unstructured":"Ahn I, et al. Where should siRNAs go: applicable organs for siRNA drugs. Exp Mol Med. 2023;55(7):1283\u201392.","journal-title":"Exp Mol Med"},{"key":"4511_CR25","doi-asserted-by":"publisher","first-page":"114416","DOI":"10.1016\/j.addr.2022.114416","volume":"188","author":"C Hald Albertsen","year":"2022","unstructured":"Hald Albertsen C, et al. The role of lipid components in lipid nanoparticles for vaccines and gene therapy. Adv Drug Deliv Rev. 2022;188:114416.","journal-title":"Adv Drug Deliv Rev"},{"issue":"9","key":"4511_CR26","doi-asserted-by":"publisher","first-page":"709","DOI":"10.1038\/s41573-024-00977-6","volume":"23","author":"PR Cullis","year":"2024","unstructured":"Cullis PR, et al. The 60-year evolution of lipid nanoparticles for nucleic acid delivery. Nat Rev Drug Discov. 2024;23(9):709\u201322.","journal-title":"Nat Rev Drug Discov"},{"key":"4511_CR27","doi-asserted-by":"publisher","first-page":"130","DOI":"10.1016\/j.jconrel.2023.07.054","volume":"361","author":"SH El Moukhtari","year":"2023","unstructured":"El Moukhtari SH, et al. Lipid nanoparticles for siRNA delivery in cancer treatment. J Control Release. 2023;361:130\u201346.","journal-title":"J Control Release"},{"issue":"12","key":"4511_CR28","doi-asserted-by":"publisher","first-page":"1084","DOI":"10.1038\/s41565-019-0591-y","volume":"14","author":"A Akinc","year":"2019","unstructured":"Akinc A, et al. The Onpattro story and the clinical translation of nanomedicines containing nucleic acid-based drugs. Nat Nanotechnol. 2019;14(12):1084\u20137.","journal-title":"Nat Nanotechnol"},{"issue":"1","key":"4511_CR29","doi-asserted-by":"publisher","first-page":"101","DOI":"10.1038\/s41392-020-0207-x","volume":"5","author":"B Hu","year":"2020","unstructured":"Hu B, et al. Therapeutic siRNA: state of the art. Signal Transduct Target Ther. 2020;5(1):101.","journal-title":"Signal Transduct Target Ther"},{"issue":"16","key":"4511_CR30","doi-asserted-by":"publisher","first-page":"e2201095","DOI":"10.1002\/adma.202201095","volume":"34","author":"R Pattipeiluhu","year":"2022","unstructured":"Pattipeiluhu R, et al. Anionic Lipid Nanoparticles Preferentially Deliver mRNA to the Hepatic Reticuloendothelial System. Adv Mater. 2022;34(16):e2201095.","journal-title":"Adv Mater"},{"issue":"2","key":"4511_CR31","doi-asserted-by":"publisher","first-page":"284","DOI":"10.1016\/j.ymthe.2024.01.005","volume":"32","author":"M Moazzam","year":"2024","unstructured":"Moazzam M, et al. The landscape of nanoparticle-based siRNA delivery and therapeutic development. Mol Ther. 2024;32(2):284\u2013312.","journal-title":"Mol Ther"},{"issue":"9","key":"4511_CR32","doi-asserted-by":"publisher","first-page":"e2409729","DOI":"10.1002\/advs.202409729","volume":"12","author":"C Lin","year":"2025","unstructured":"Lin C, et al. Exceptional Uptake, Limited Protein Expression: Liver Macrophages Lost in Translation of Synthetic mRNA. Adv Sci (Weinh). 2025;12(9):e2409729.","journal-title":"Adv Sci (Weinh)"},{"issue":"15","key":"4511_CR33","doi-asserted-by":"publisher","first-page":"1633","DOI":"10.1182\/blood.2023023349","volume":"144","author":"ME Chappell","year":"2024","unstructured":"Chappell ME, et al. Use of HSC-targeted LNP to generate a mouse model of lethal \u03b1-thalassemia and treatment via lentiviral gene therapy. Blood. 2024;144(15):1633\u201345.","journal-title":"Blood"},{"issue":"11","key":"4511_CR34","doi-asserted-by":"publisher","first-page":"1813","DOI":"10.1038\/s41587-024-02470-2","volume":"43","author":"H Kim","year":"2025","unstructured":"Kim H, et al. Lipid nanoparticle-mediated mRNA delivery to CD34(+) cells in rhesus monkeys. Nat Biotechnol. 2025;43(11):1813\u201320.","journal-title":"Nat Biotechnol"},{"key":"4511_CR35","doi-asserted-by":"publisher","first-page":"114030","DOI":"10.1016\/j.jconrel.2025.114030","volume":"385","author":"K Miyasaki","year":"2025","unstructured":"Miyasaki K, et al. Formulation methods for peptide-modified lipid nanoparticles. J Control Release. 2025;385:114030.","journal-title":"J Control Release"},{"key":"4511_CR36","doi-asserted-by":"publisher","first-page":"120439","DOI":"10.1016\/j.carbpol.2022.120439","volume":"303","author":"X Zhang","year":"2023","unstructured":"Zhang X, et al. Hepatoma-targeting and reactive oxygen species-responsive chitosan-based polymeric micelles for delivery of celastrol. Carbohydr Polym. 2023;303:120439.","journal-title":"Carbohydr Polym"},{"issue":"11","key":"4511_CR37","doi-asserted-by":"publisher","first-page":"2958","DOI":"10.1007\/s12274-020-2954-y","volume":"13","author":"SY Shen","year":"2020","unstructured":"Shen SY, et al. Collaborative assembly-mediated siRNA delivery for relieving inflammation-induced insulin resistance. Nano Res. 2020;13(11):2958\u201366.","journal-title":"Nano Res"},{"issue":"9","key":"4511_CR38","doi-asserted-by":"publisher","first-page":"eabf4398","DOI":"10.1126\/sciadv.abf4398","volume":"7","author":"M Kim","year":"2021","unstructured":"Kim M, et al. Engineered ionizable lipid nanoparticles for targeted delivery of RNA therapeutics into different types of cells in the liver. Sci Adv. 2021;7(9):eabf4398.","journal-title":"Sci Adv"},{"issue":"1","key":"4511_CR39","doi-asserted-by":"publisher","first-page":"105","DOI":"10.1158\/0008-5472.CAN-21-2269","volume":"82","author":"H Sendi","year":"2022","unstructured":"Sendi H, et al. Nanoparticle Delivery of miR-122 Inhibits Colorectal Cancer Liver Metastasis. Cancer Res. 2022;82(1):105\u201313.","journal-title":"Cancer Res"},{"issue":"1","key":"4511_CR40","doi-asserted-by":"publisher","first-page":"1","DOI":"10.7150\/thno.89913","volume":"14","author":"SK Patel","year":"2024","unstructured":"Patel SK, et al. Bile acid-containing lipid nanoparticles enhance extrahepatic mRNA delivery. Theranostics. 2024;14(1):1\u201316.","journal-title":"Theranostics"},{"issue":"5","key":"4511_CR41","doi-asserted-by":"publisher","first-page":"1801809","DOI":"10.1002\/advs.201801809","volume":"6","author":"J Wu","year":"2019","unstructured":"Wu J, et al. Synergistic MicroRNA Therapy in Liver Fibrotic Rat Using MRI-Visible Nanocarrier Targeting Hepatic Stellate Cells. Adv Sci (Weinh). 2019;6(5):1801809.","journal-title":"Adv Sci (Weinh)"},{"issue":"3","key":"4511_CR42","doi-asserted-by":"publisher","first-page":"723","DOI":"10.1083\/jcb.201607091","volume":"216","author":"A Qiao","year":"2017","unstructured":"Qiao A, et al. The transcriptional regulator of the chaperone response HSF1 controls hepatic bioenergetics and protein homeostasis. J Cell Biol. 2017;216(3):723\u201341.","journal-title":"J Cell Biol"},{"issue":"1","key":"4511_CR43","doi-asserted-by":"publisher","first-page":"8380","DOI":"10.1038\/s41467-025-63651-4","volume":"16","author":"DA Estabrook","year":"2025","unstructured":"Estabrook DA, et al. Buffer optimization of siRNA-lipid nanoparticles mitigates lipid oxidation and RNA-lipid adduct formation. Nat Commun. 2025;16(1):8380.","journal-title":"Nat Commun"},{"issue":"15","key":"4511_CR44","doi-asserted-by":"publisher","first-page":"3789","DOI":"10.1016\/j.cell.2024.06.029","volume":"187","author":"ED Abel","year":"2024","unstructured":"Abel ED, et al. Diabetes mellitus-Progress and opportunities in the evolving epidemic. Cell. 2024;187(15):3789\u2013820.","journal-title":"Cell"},{"issue":"1","key":"4511_CR45","doi-asserted-by":"publisher","first-page":"5354","DOI":"10.1038\/s41467-025-60959-z","volume":"16","author":"JM Johansson","year":"2025","unstructured":"Johansson JM, et al. Cellular and biophysical barriers to lipid nanoparticle mediated delivery of RNA to the cytosol. Nat Commun. 2025;16(1):5354.","journal-title":"Nat Commun"},{"issue":"6","key":"4511_CR46","doi-asserted-by":"publisher","first-page":"630","DOI":"10.1038\/s41565-021-00898-0","volume":"16","author":"JA Kulkarni","year":"2021","unstructured":"Kulkarni JA, et al. The current landscape of nucleic acid therapeutics. Nat Nanotechnol. 2021;16(6):630\u201343.","journal-title":"Nat Nanotechnol"},{"issue":"20","key":"4511_CR47","doi-asserted-by":"publisher","first-page":"4759","DOI":"10.1039\/D3TB02766J","volume":"12","author":"R Chu","year":"2024","unstructured":"Chu R, et al. Lipid nanoparticles as the drug carrier for targeted therapy of hepatic disorders. J Mater Chem B. 2024;12(20):4759\u201384.","journal-title":"J Mater Chem B"},{"issue":"49","key":"4511_CR48","doi-asserted-by":"publisher","first-page":"16958","DOI":"10.1021\/ja505986a","volume":"136","author":"JK Nair","year":"2014","unstructured":"Nair JK, et al. Multivalent N-acetylgalactosamine-conjugated siRNA localizes in hepatocytes and elicits robust RNAi-mediated gene silencing. J Am Chem Soc. 2014;136(49):16958\u201361.","journal-title":"J Am Chem Soc"},{"issue":"9","key":"4511_CR49","doi-asserted-by":"publisher","first-page":"1384","DOI":"10.1038\/s41591-018-0125-4","volume":"24","author":"AK Madiraju","year":"2018","unstructured":"Madiraju AK, et al. Metformin inhibits gluconeogenesis via a redox-dependent mechanism in vivo. Nat Med. 2018;24(9):1384\u201394.","journal-title":"Nat Med"},{"issue":"3","key":"4511_CR50","doi-asserted-by":"publisher","first-page":"E620","DOI":"10.1152\/ajpendo.00069.2016","volume":"311","author":"T Jin","year":"2016","unstructured":"Jin T, et al. Hepatic functions of GLP-1 and its based drugs: current disputes and perspectives. Am J Physiology-Endocrinology Metabolism. 2016;311(3):E620\u20137.","journal-title":"Am J Physiology-Endocrinology Metabolism"},{"issue":"1","key":"4511_CR51","doi-asserted-by":"publisher","first-page":"83","DOI":"10.1186\/1743-7075-7-83","volume":"7","author":"H Ito","year":"2010","unstructured":"Ito H, et al. Long-term effect of metformin on blood glucose control in non-obese patients with type 2 diabetes mellitus. Nutr Metabolism. 2010;7(1):83.","journal-title":"Nutr Metabolism"},{"issue":"1","key":"4511_CR52","doi-asserted-by":"publisher","first-page":"184","DOI":"10.3390\/cells9010184","volume":"9","author":"S Peng","year":"2020","unstructured":"Peng S, et al. A review of FoxO1-regulated metabolic diseases and related drug discoveries. Cells. 2020;9(1):184.","journal-title":"Cells"},{"key":"4511_CR53","doi-asserted-by":"publisher","first-page":"155371","DOI":"10.1016\/j.metabol.2022.155371","volume":"139","author":"E Thymiakou","year":"2023","unstructured":"Thymiakou E, et al. Impaired hepatic glucose metabolism and liver-\u03b1-cell axis in mice with liver-specific ablation of the Hepatocyte Nuclear Factor 4\u03b1 (Hnf4a) gene. Metabolism. 2023;139:155371.","journal-title":"Metabolism"},{"issue":"16","key":"4511_CR54","doi-asserted-by":"publisher","first-page":"4486","DOI":"10.1093\/nar\/gkl609","volume":"34","author":"AT De Souza","year":"2006","unstructured":"De Souza AT, et al. Transcriptional and phenotypic comparisons of Ppara knockout and siRNA knockdown mice. Nucleic Acids Res. 2006;34(16):4486\u201394.","journal-title":"Nucleic Acids Res"},{"issue":"11","key":"4511_CR55","doi-asserted-by":"publisher","first-page":"6020","DOI":"10.1093\/nar\/gkac456","volume":"50","author":"SC Humphreys","year":"2022","unstructured":"Humphreys SC, et al. Considerations and recommendations for assessment of plasma protein binding and drug-drug interactions for siRNA therapeutics. Nucleic Acids Res. 2022;50(11):6020\u201337.","journal-title":"Nucleic Acids Res"},{"issue":"1","key":"4511_CR56","doi-asserted-by":"publisher","first-page":"11","DOI":"10.1056\/NEJMoa1716153","volume":"379","author":"D Adams","year":"2018","unstructured":"Adams D, et al. Patisiran, an RNAi Therapeutic, for Hereditary Transthyretin Amyloidosis. N Engl J Med. 2018;379(1):11\u201321.","journal-title":"N Engl J Med"}],"container-title":["Journal of Nanobiotechnology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12951-026-04511-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12951-026-04511-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,7,10]],"date-time":"2026-07-10T05:02:33Z","timestamp":1783659753000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12951-026-04511-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,5,14]]},"references-count":56,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["4511"],"URL":"https:\/\/doi.org\/10.1186\/s12951-026-04511-1","relation":{},"ISSN":["1477-3155"],"issn-type":[{"value":"1477-3155","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,5,14]]},"assertion":[{"value":"19 January 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"21 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"14 May 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no competing interests.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"640"}}